At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Daratumumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Daratumumab Infusion Acceleration
Ohio State University Comprehensive Cancer Center·interventional·Posted Oct 26, 2016·Updated Sep 9, 2019
In Brief
A Phase 2 clinical trial evaluating Daratumumab for Plasma Cell Myeloma. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and how well daratumumab works in treating patients with multiple myeloma when the infusion is accelerated. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlasma Cell Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartFeb 2017
Primary CompletionJul 2017
TodayJul 2026
First PostedOct 26, 2016
Enrollment StartFeb 22, 2017
Primary CompletionJul 20, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.7 years ago
Interventions
Daratumumabbiological
Given IV